The Bland-Altman plot below is a visual representation of the agreement of the MARV plaque counts made by the two analysts for each Precision experiment. The difference between counts of each well are plotted on the y-axis, while the mean of the two counts for each well are plotted on the x-axis. The central reference line in each plot is the mean of the differences between counts; while the two other reference lines represent two standard deviations of the differences above and below the mean. It appears that the fewer the plaques counted, the closer the data fell to that central reference line: therefore, it is possible that when there are fewer plaques to count, there is less variation between two analysts. The Bland-Altman analysis results for MARV are very similar to those seen for the EBOV analysis. The validation protocol acceptance criterion for stability was that the F/S sample had to return a titer no more than 30% different from the value measured for the non-freeze-thawed sample to demonstrate that freeze-thawing had no detrimental effect on the sample. Consistently, less than a 30% difference was observed for the MARV cell culture samples, where the widest difference from the untreated sample was 12.4% for MARV QC1 (see below). Statistical comparison by Student's t-test of the treated versus untreated samples demonstrated no statistical significance between any of
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